Patent: 8,119,134
✉ Email this page to a colleague
Summary for Patent: 8,119,134
| Title: | Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia |
| Abstract: | A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity. |
| Inventor(s): | Adair; Charles David (Signal Mountain, TN) |
| Assignee: | Glenveigh Pharmaceuticals, LLC (Chattanooga, TN) |
| Application Number: | 12/849,651 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,119,134
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Wellcome Foundation Limited Wellcome Research Laboratories | DIGIBIND | digoxin immune fab (ovine) | For Injection | 103141 | 04/22/1986 | ⤷ Try a Trial | 2022-07-25 |
| Btg International Inc. | DIGIFAB | digoxin immune fab (ovine) | For Injection | 103910 | 08/31/2001 | ⤷ Try a Trial | 2022-07-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
